RetinalGenix Technologies (RTGN) Cash & Equivalents (2020 - 2026)
RetinalGenix Technologies (RTGN) reported Cash & Equivalents of $180.0 for Q1 2026, down 95.15% on a YoY basis from $3711.0 in Q1 2025, and down 98.78% sequentially from $14774.0 in Q4 2025.
RetinalGenix Technologies (RTGN) Cash & Equivalents (2020 - 2026) Analysis & Trends
RetinalGenix Technologies (RTGN) has 7 years of Cash & Equivalents data on file, last reported at $180.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash & Equivalents fell 95.15% year-over-year to $180.0; the trailing twelve-month figure through Mar 2026 stood at $180.0 (down 95.15% YoY), and the FY2025 full-year result was $14774.0, up 143.8% from the prior year.
- Cash & Equivalents declined to $180.0 in Q1 2026, from $14774.0 in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $86913.0 in Q2 2024 to a low of $27.0 in Q2 2022.
- A 5-year average of $16107.7 and a median of $3093.5 in 2022 frame the typical range for Cash & Equivalents.
- Across the five-year window, Cash & Equivalents soared 179647.73% in 2024 and tumbled 99.88% in 2025, its largest moves.
- Tracing RTGN's Cash & Equivalents over 5 years: stood at $38.0 in 2022, then grew by 15.79% to $44.0 in 2023, then jumped by 13672.73% to $6060.0 in 2024, then soared by 143.8% to $14774.0 in 2025, then plunged by 98.78% to $180.0 in 2026.
- Business Quant data shows RTGN's Cash & Equivalents at $180.0 in Q1 2026, $14774.0 in Q4 2025, and $92.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 6.80 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 2.88 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 1.95 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 1.45 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 2.45 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 1.12 Bn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 3.03 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 2.29 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | 557.00 Mn |
| 10 | RetinalGenix Technologies | 75.02 Mn | 75.02 Mn | - | 180.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 180.00 |
| Dec 31, 2025 | 14,774.00 |
| Sep 30, 2025 | 92.00 |
| Jun 30, 2025 | 839.00 |
| Mar 31, 2025 | 3,711.00 |
| Dec 31, 2024 | 6,060.00 |
| Sep 30, 2024 | 79,089.00 |
| Jun 30, 2024 | 86,913.00 |
| Mar 31, 2024 | 50,386.00 |
| Sep 30, 2023 | 44.00 |
| Jun 30, 2023 | 1,913.00 |
| Mar 31, 2023 | 7,470.00 |
| Dec 31, 2022 | 38.00 |
| Sep 30, 2022 | 3,632.00 |
| Jun 30, 2022 | 27.00 |
| Mar 31, 2022 | 2,555.00 |
| Dec 31, 2021 | 4,947.00 |
| Sep 30, 2021 | 36,578.00 |
| Dec 31, 2020 | 2,219.00 |